{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:07:24Z","timestamp":1779361644524,"version":"3.51.4"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HLA"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Patients treated with etrolizumab, a monoclonal antibody drug for ulcerative colitis, often develop anti\u2010drug antibodies (ADA) and neutralising antibodies (NAb). To investigate genetic risk factors, we evaluated associations between HLA alleles and ADA\/NAb development.\n                    <jats:italic>HLA\u2010DQB1*06:03<\/jats:italic>\n                    demonstrated the most significant association with both ADA (OR\u2009=\u20097.3,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20097.6\u2009\u00d7\u200910\n                    <jats:sup>\u221213<\/jats:sup>\n                    ) and NAb (OR\u2009=\u200913.1,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20097.7\u2009\u00d7\u200910\n                    <jats:sup>\u221213<\/jats:sup>\n                    ). After controlling for\n                    <jats:italic>HLA\u2010DQB1*06:03<\/jats:italic>\n                    ,\n                    <jats:italic>HLA\u2010DQA1*03:03<\/jats:italic>\n                    emerged as the next most significant allele associated with ADA (OR\u2009=\u20092.8,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20091.0\u2009\u00d7\u200910\n                    <jats:sup>\u22123<\/jats:sup>\n                    ) and NAb (OR\u2009=\u20095.0,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009\u2264\u20091.3\u2009\u00d7\u200910\n                    <jats:sup>\u22123<\/jats:sup>\n                    ). Notably, all patients carrying both alleles (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095) developed ADA, suggesting these two alleles are sufficient to induce ADA to etrolizumab.\n                  <\/jats:p>","DOI":"10.1111\/tan.70557","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:55:36Z","timestamp":1770353736000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>HLA<\/scp>\n                    Class\n                    <scp>II<\/scp>\n                    Alleles Are Associated With Anti\u2010Drug Antibodies in Ulcerative Colitis Patients Treated With Etrolizumab"],"prefix":"10.1111","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3203-2114","authenticated-orcid":false,"given":"Ashis","family":"Saha","sequence":"first","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark I.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloumeh K.","family":"Fischer","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gizette","family":"Sperinde","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hammer","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(21)00298\u20103"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(21)00295\u20108"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(21)00294\u20106"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090479"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.041"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13264"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23230"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2018.07.015"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.18"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1101\/gr.094052.109"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz1029"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206512"}],"container-title":["HLA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tan.70557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tan.70557","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tan.70557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:41:26Z","timestamp":1779360086000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tan.70557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/tan.70557"],"URL":"https:\/\/doi.org\/10.1111\/tan.70557","archive":["Portico"],"relation":{},"ISSN":["2059-2302","2059-2310"],"issn-type":[{"value":"2059-2302","type":"print"},{"value":"2059-2310","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70557"}}